S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours
Authors:
- 1 September 2013
- journal article
- guideline
- Published by Georg Thieme Verlag KG in Geburtshilfe und Frauenheilkunde
- Vol. 73 (09) , 874-889
Abstract
German Guideline Programme in Oncology (OL) of the Association of the Scientific Medical Societies in Germany (AWMF), the German Cancer Society (DKG) and German Cancer Aid (DKH). Germany Society for Gynaecology and Obstetrics (DGGG). This guideline was funded by German Cancer Aid as part of the German Guideline Programme in Oncology. Office of the German Guideline Programme in Oncology c/o Deutsche Krebsgesellschaft e. V. Kuno-Fischer-Straße 8 14 057 Berlin, Germany leitlinienprogramm@krebsgesellschaft.de www.leitlinienprogramm-onkologie.de The German Guideline Programme in Oncology (German Cancer Society, German Cancer Aid, AWMF): S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumors, short version 1.0 (2013), AWMF registration number: 032–035OL, http://leitlinienprogramm-onkologie.de/Leitlinien.7.0.html The contents of this short version refer to the long version of the S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours available in German on the following websites In addition to the short version, a number of other, supplementary documents are also available: All of these documents will also be available on the websites listed above. Editorial team Participating scientific societies and authors Methodological SupportKeywords
This publication has 229 references indexed in Scilit:
- Fertility‐Sparing Options for Patients with Gynecologic MalignanciesThe Oncologist, 2005
- Positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancerInternational Journal of Clinical Oncology, 2005
- Impact of surgical staging in patients with macroscopic “stage I” ovarian borderline tumours: analysis of a continuous series of 101 casesEuropean Journal of Cancer, 2004
- Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 StudiesThe American Journal of Human Genetics, 2003
- The BRCA1 syndrome and other inherited breast or breast–ovarian cancers in a Norwegian prospective seriesEuropean Journal of Cancer, 2001
- Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinomaThe Lancet, 2001
- Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year ResultsJNCI: Journal of the National Cancer Institute, 2000
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- National survey of ovarian carcinoma part V. The impact of physician's specialty on patients' survivalCancer, 1993
- Adjuvant Therapy in Stage I and Stage II Epithelial Ovarian CancerNew England Journal of Medicine, 1990